TFF Pharmaceuticals to Participate in Jefferies Virtual Healthcare Conference

Rhea-AI Summary

TFF Pharmaceuticals (NASDAQ: TFFP) will present a corporate overview at the Jefferies Virtual Healthcare Conference on June 1, 2021, at 11:30am EST. The company focuses on innovative drug products using its patented Thin Film Freezing technology, enhancing the solubility of poorly water-soluble drugs, which represent one-third of major pharmaceuticals. TFF Pharmaceuticals is advancing its lead candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder and aims to expand its pipeline through partnerships. A replay of the presentation will be available on their website.

AUSTIN, Texas, May 25, 2021 (GLOBE NEWSWIRE) -- TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that management will present a corporate overview at the Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:30am EST.

To register in advance for the corporate presentation, sign up here.

Replay Link:
A replay will be accessible on the Events & Presentations page of the Investors section on the Company’s website at https://ir.tffpharma.com/events-and-presentations/events

About TFF Pharmaceuticals
TFF Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing, or TFF, technology platform. Early testing confirms that the TFF platform can significantly improve the solubility and absorption of poorly water-soluble drugs, a class of drugs that comprises approximately one-third of the major pharmaceuticals worldwide, thereby improving their pharmacokinetics. TFF Pharmaceuticals has two lead drug candidates: Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder. The Company plans to add to this pipeline by collaborating with large pharmaceutical partners. The TFF Platform is protected by 42 patents issued or pending in the US and internationally. To learn more about TFF Pharmaceuticals and its product candidates, visit the Company’s website at https://tffpharma.com.

Company Contacts:

Glenn Mattes
President and CEO
TFF Pharmaceuticals, Inc
gmattes@tffpharma.com
737-802-1973

Kirk Coleman
Chief Financial Officer
TFF Pharmaceuticals, Inc.
kcoleman@tffpharma.com
817-989-6358

Investor Relations Contact: 
Corey Davis, Ph.D. 
LifeSci Advisors 
212-915-2577 
cdavis@lifesciadvisors.com

Media Contact:
Gwendolyn Schanker
LifeSci Communications
(269) 921-3607
gschanker@lifescicomms.com 

FAQ

What is TFF Pharmaceuticals' stock symbol?

TFF Pharmaceuticals is traded under the stock symbol TFFP.

When will TFF Pharmaceuticals present at the Jefferies Virtual Healthcare Conference?

TFF Pharmaceuticals will present on June 1, 2021, at 11:30am EST.

What technology does TFF Pharmaceuticals use for drug development?

TFF Pharmaceuticals utilizes its patented Thin Film Freezing technology for developing innovative drug products.

What are the lead drug candidates of TFF Pharmaceuticals?

The lead drug candidates of TFF Pharmaceuticals are Voriconazole Inhalation Powder and Tacrolimus Inhalation Powder.

How can investors access the replay of TFF Pharmaceuticals' presentation?

Investors can access the replay on the Events & Presentations page of TFF Pharmaceuticals' website.